Skip to content

The Effect of Transcranial Direct Current Stimulation (tDCS) on Depression in PD

The Effect of Transcranial Direct Current Stimulation (tDCS) on Depression in Parkinson's Disease

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03227783
Enrollment
26
Registered
2017-07-24
Start date
2019-02-28
Completion date
2021-12-31
Last updated
2018-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Brief summary

Depression is common in Parkinson's disease (PD), but the effective treatment is not established yet. tDCS is a non-invasive brain stimulation to modulate brain function. The tDCS on the depression in general population were already conducted, but not in PD. This study is to know whether transcranial direct current stimulation (tDCS) is effective for the treatment of depression in PD. Participant will be asked to visit three consecutive days for the non-invasive stimulation.

Interventions

DEVICEtranscranial direct current stimulation (tDCS)

tDCS is one of non-invasive brain stimulation. Constant, low current is delivered to the specific brain areas to change brain plasticity.

Sponsors

Inje University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Intervention model description

Randomized, Parallel, Sham-controlled, single-blinded study

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* UK Parkinson's disease brain bank criteria * more than 19 years old * Able to provide consent for the protocol * Depression (based on DSM-IV criteria)

Exclusion criteria

* Dementia * Unpredictable symptom fluctuations * Contraindication to tDCS (i) irritations, cuts, lesions in the brain (ii) any preexisting unstable medical conditions, or conditions that may increase the risk of stimulation such as uncontrolled epilepsy (iii) history of severe cranial trauma with alteration of the cranial anatomy or metallic intracranial implants (iv) history of seizure * Subjects without the capacity to give informed consent * If participation in the study would, in the opinion of the investigators, cause undue risk or stress for reasons such as excessive fatigue, general frailty, or excessive apprehension

Design outcomes

Primary

MeasureTime frameDescription
BDI score(1) before the1st visit (within one month) (2) right after the 3rd tDCS (3) within one months after the 3rd tDCSThe changes of Beck depression inventory after tDCS

Secondary

MeasureTime frameDescription
HDRS score(1) before the 1st visit (within one month) (2) right after 3rd tDCS, within 24 hours (3) within one months after the 3rd tDCSThe changes of Hamilton Depression Rating Scale after tDCS
MADRS score(1) before the 1st visit (within one month) (2) right after the 3rd tDCS, within 24 hours (3) within one months after 3rd tDCSThe changes of Mongomery-Asberg Depression Rating Scale after tDCS
resting state functional MRI(1) before the 1st visit (within one month) (2) after the 3rd tDCS, within 24 hours (on the same day as the 3rd tDCS)The changes of resting state functional MRI after tDCS

Countries

South Korea

Contacts

Primary ContactSang Jin Kim, MD, PhD
jsk120@hanmail.net82-51-890-8954

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026